Role of IL-23 signaling in the progression of premalignant oral lesions to cancer

Caughron, Blaine; Yang, Yi; Young, Matthew R.

doi:10.1371/journal.pone.0196034

Cited by 16 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This effect would be associated with their reduced production of IL-23 and increased production of TGF-β [53]. Additionally, Caughron et al showed that IL-23 can perform a pro-inflammatory function in precancerous lesions but activates an inhibitory function in the later stages of neoplastic development [54].…”

Section: Oral Leukoplakia: Immunopathology and Rationale For The Use mentioning

confidence: 99%

Leukoplakia and Immunology: New Chemoprevention Landscapes?

Grigolato

Bizzoca

Calabrese

et al. 2020

IJMS

View full text Add to dashboard Cite

Oral potentially malignant disorders (OPMDs) comprise a range of clinical-pathological alterations frequently characterized by an architectural and cytological derangements upon histological analysis. Among them, oral leukoplakia is the most common type of these disorders. This work aims to analyze the possible use of drugs such as immunochemopreventive agents for OPMDs. Chemoprevention is the use of synthetic or natural compounds for the reversal, suppression, or prevention of a premalignant lesion conversion to malignant form. Experimental and in vivo data offer us the promise of molecular prevention through immunomodulation; however, currently, there is no evidence for the efficacy of these drugs in the chemoprevention action. Alternative ways to deliver drugs, combined use of molecules with complementary antitumor activities, diet influence, and better definition of individual risk factors must also be considered to reduce toxicity, improve compliance to the protocol treatment and offer a better individualized prevention. In addition, we must carefully reconsider the mode of action of many traditional cancer chemoprevention agents on the immune system, such as enhancing immunosurveillance and reversing the immune evasion. Several studies emphasize the concept of green chemoprevention as an alternative approach to accent healthy lifestyle changes in order to decrease the incidence of HNSCC.

show abstract

Section: Oral Leukoplakia: Immunopathology and Rationale For The Use mentioning

confidence: 99%

Leukoplakia and Immunology: New Chemoprevention Landscapes?

Grigolato

Bizzoca

Calabrese

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Recent studies revealed that expression of the heterodimeric cytokine interleukin (IL)-23 is increased in human tumours, for IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration [29]. IL-23 has also been proved of its tumor-promoting effect in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment [30][31][32][33][34]. Recent study also showed that IL-23-induced immune cell activation aggravates gut inflammation and promotes growth of colon cancer [35].…”

Section: Introductionmentioning

confidence: 99%

IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model

et al. 2020

View full text Add to dashboard Cite

Background: Prostate cancer is one of the most common adult malignancies in men, and nearly all patients with metastatic prostate cancer can develop and receive resistance to primary androgen deprivation therapy (ADT), a state known as metastatic castration-resistant prostate cancer (mCRPC). Recent reports demonstrated the great breakthroughs made by the chimeric antigen receptor T (CAR-T) cell therapy, which is significantly different from traditional T cells therapies. In spite of the progress of CART technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CART technology. Methods: In this report, we designed a panel of IL23mAb-PSMA-CARs, including PSMA-CAR, IL23mAb-T2A-PSMA-CAR, IL23mAb-PSMA-CAR, and PSMA-CAR (soluble IL23mAb). And we studied the function of these CARs in mice model. Results: Co-culture experiments with different CAR T cells have normal lysis function in vitro. The duo-CAR T cells coexpressing the IL-23mAb and PSMA-mAb had a significant higher population than the rest three different CAR T cells in co-culturing experiments at day 28, 35 and 42. A panel of cytokines were differentially secreted at higher amounts in IL23mAb-T2A-PSMA-CAR T cells than CAR T cells in other groups. In NOD/SCID IL-2 gamma (NSG) mice model, IL23mAb-T2A-PSMA-CAR T cells functioned significantly better than CAR T cells from the other groups and eradicated the tumor from these mice starting at day 14 post T cells injection and regained the body weight immediately. In IL23mAb-T2A-PSMA-CAR mice, CD45RO+ CD8+ T cells and CD127+ CD4+ CAR T cells were significantly increased. RNA sequencing revealed a difference expression pattern of genes in IL23mAb-T2A-PSMA-CAR mice. A reverse infusion experiment under the same model further proved the tumor eradication function of IL23mAb-T2A-PSMA-CAR T cells. Conclusions: We found that IL-23mAb combined PSMA CARs worked better than PSMA CAR only in Prostate Cancer Eradication, and we further discussed the mechanisms among different IL-23mAb combined PSMA CARs in Prostate Cancer Eradication.

show abstract

“…IL‐23 leads to the differentiation of CD8 + T cells into an enhanced pro‐inflammatory Tc17 subset . The reduction of this subset after treatment could promote a tumor permissive environment . High levels of IL‐22 secreting Tc‐22 cells are associated with poor prognosis in squamous cell carcinoma .…”

Section: Resultsmentioning

confidence: 99%

Exposure to anti‐PD‐1 causes functional differences in tumor‐infiltrating lymphocytes in rare solid tumors

Creasy

Forget

Singh³

et al. 2019

Eur J Immunol

View full text Add to dashboard Cite

The pervasive use of therapeutic antibodies targeting programmed cell death protein 1 (PD-1) to boost anti-tumor immunity has positioned this approach to become the standard-of-care for some solid tumor malignancies. However, little is known as to how blockade of PD-1 may alter the function or phenotype of tumor-infiltrating lymphocytes (TIL). We used our ongoing Phase II clinical trial of pembrolizumab for patients with rare solid tumors from various types (NCT02721732) with matched core biopsies taken at baseline and after initial dose of anti-PD-1 (15-21 days post-dose) to elucidate this question. One fresh core needle biopsy was used to propagate TIL ex vivo to analyze phenotype and function using flow cytometry in both CD8 + and CD4 + TIL populations. An enriched CTLA-4 expression in the CD4 + TIL population was observed in TIL expanded from the on-treatment samples compared to TIL expanded from the matched baseline (n = 22, p = 0.0007) but was not observed in patients who experienced tumor regression. Impact on functionality was evaluated by measuring secretion of 65 soluble factors by expanded TIL from 26 patients at baseline and on-treatment. The CD8 + TIL population demonstrated a diminished cytokine secretion profile post-pembrolizumab. Overall, our study assesses the ramifications of one dose of anti-PD-1 on TIL in rare solid tumor types.Keywords: Anti-PD-1 r CTLA-4 r Immunotherapy r Rare solid tumors r TIL Additional supporting information may be found online in the Supporting Information section at the end of the article.

show abstract

Role of IL-23 signaling in the progression of premalignant oral lesions to cancer

Cited by 16 publications

References 32 publications

Leukoplakia and Immunology: New Chemoprevention Landscapes?

Leukoplakia and Immunology: New Chemoprevention Landscapes?

IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model

Exposure to anti‐PD‐1 causes functional differences in tumor‐infiltrating lymphocytes in rare solid tumors

Contact Info

Product

Resources

About